Antibiotic resistance is on the rise and scientists are on the lookout for new therapeutics for treating human pathogens. One promising new venture repurposes antimalarial drugs to treat patients with chronic lung diseases such as cystic fibrosis.
Researchers no longer think that proteins blindly swim through the cytoplasm hoping to bump into one another. Instead, they intentionally aggregate with other biomolecules, forming membrane free, transient organelles called condensates.
COVID-19 has gotten a little better at infecting cells and dodging antibodies with each set of mutations in new variants. Omicron is the best at dodging antibodies, but its modified structure sacrificed virulence for antibody resistance.